Dyne Therapeutics (DYN)
(Delayed Data from NSDQ)
$44.88 USD
-1.65 (-3.55%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $44.89 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Dyne Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -235.94 | -168.10 | -149.29 | -59.44 | -14.86 |
Depreciation/Amortization & Depletion | 0.57 | 2.96 | 3.67 | 0.78 | 0.27 |
Net Change from Assets/Liabilities | 26.31 | -5.38 | 9.26 | 5.11 | 1.41 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 20.90 | 16.87 | 16.80 | 7.04 | 1.35 |
Net Cash From Operating Activities | -188.16 | -153.65 | -119.56 | -46.51 | -11.83 |
Property & Equipment | -0.73 | -3.07 | -3.62 | -1.16 | -1.65 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 84.04 | 90.27 | -134.27 | -44.50 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 83.31 | 87.20 | -137.89 | -45.66 | -1.65 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 54.32 | 37.39 | 157.82 | 381.20 | 19.99 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | -0.06 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | -0.45 | 0.00 |
Net Cash from Financing Activities | 54.32 | 37.39 | 157.82 | 380.69 | 19.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -50.53 | -29.05 | -99.63 | 288.52 | 6.51 |
Cash at Beginning of Period | 174.47 | 203.52 | 303.15 | 14.63 | 8.12 |
Cash at End of Period | 123.94 | 174.47 | 203.52 | 303.15 | 14.63 |
Diluted Net EPS | -3.95 | -3.23 | -2.93 | -4.13 | NA |
Fiscal Year End for Dyne Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -130.75 | -65.65 | -235.94 | -169.30 | -109.09 |
Depreciation/Amortization & Depletion | -1.01 | -0.14 | 0.57 | 0.37 | 0.30 |
Net Change from Assets/Liabilities | -28.59 | -32.83 | 26.31 | 0.78 | -3.72 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 26.94 | 20.08 | 20.90 | 15.00 | 9.96 |
Net Cash From Operating Activities | -133.41 | -78.54 | -188.16 | -153.15 | -102.55 |
Property & Equipment | -1.05 | -0.19 | -0.73 | -0.65 | -0.48 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -167.62 | -179.65 | 84.04 | 57.76 | 44.77 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -168.66 | -179.84 | 83.31 | 57.12 | 44.29 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 788.25 | 408.39 | 54.32 | 54.18 | 53.72 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 788.25 | 408.39 | 54.32 | 54.18 | 53.72 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 486.18 | 150.01 | -50.53 | -41.86 | -4.54 |
Cash at Beginning of Period | 123.94 | 123.94 | 174.47 | 174.47 | 174.47 |
Cash at End of Period | 610.12 | 273.96 | 123.94 | 132.60 | 169.93 |
Diluted Net EPS | -0.70 | -0.81 | -1.10 | -0.99 | -1.08 |